Search
for
Sort by
Research 271–300 of 1000+
- JAK-centric explainable few-shot gene-expression diagnosis framework for alopecia via MultiPLIER priors and relation-style set-to-set comparison
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Grand challenges in dermatologic drug discovery: four priorities to transform skin disease treatment
- Tangled Causes, Targeted Solutions: A Comprehensive Review of Alopecia.
- A decade of progress in androgenetic alopecia management: Emerging therapies and multimodal strategies
- 15-Hydroxyprostaglandin Dehydrogenase Inhibitor Restores Endothelial Function Under Dihydrotestosterone-Induced Stress in Human Dermal Microvascular Endothelial Cells
- SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
- Hair for the Long Haul: Alopecia Areata Cases and Considerations
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- Modern and Promising Strategies for Treatment of Alopecia in the United States: Clinical and Pharmacological, Marketing, Regulatory, SWOT Analysis
- Natural Product-Inspired Bis(trifluoromethyl) Phenyl Hydroxycinnamate Derivatives as Promising Nonsteroidal Inhibitors of Human Steroid 5α-Reductase Type-1: Synthesis, <i>In Vitro</i>, and <i>In Silico</i> Studies
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- A Natural Inhibitor, 1′S-1′-Acetoxychavicol Acetate, Against Testosterone-Induced Alopecia via NADPH Oxidase Regulation
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Impacto del desequilibrio del microbioma del cuero cabelludo en la severidad de la alopecia areata, marcadores inflamatorios y cambios post-tratamiento
- Farmácia Padrão da Légua, Custóias e nos Serviços Farmacêuticos da Klinicka Bolnica Dubrava, Croácia
- Turning JAK STATic, a peek into the future of dermatology therapeutics
- Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe?
- Farmácia da Cruz, Porto e Serviços Farmacêuticos do Hospital General Universitario Gregorio Marañón, Espanha
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- BH03: Systemic sclerosis and frontal fibrosing alopecia: a novel combination of scarring alopecia
- 1325 Age-dependent loss of the stemness and antimicrobial defense function of dermal fibroblasts is mediated by TGFbeta
- Topical JAK Inhibitors for the Treatment of Alopecia Areata and Vitiligo
- Cutaneous Lupus Erythematosus
- Increased cAMP levels in human hair follicles due to local treatment with trichoriboside.
- Corticosterone inhibits GAS6 to govern hair follicle stem-cell quiescence
- Ruxolitinib for the treatment of severe alopecia areata
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials